In connection with the annual report, Novo Nordisk reports a full-year sales of 290 billion Danish kronor, while the market on average had forecast sales of 285.6 billion according to Bloomberg's compilation.
This is an increase of 25 percent compared to 2023, reports the Danish news agency Ritzau.
At the same time, the company reports a surplus of 101 billion kronor, which is an increase of 21 percent.
Far above expectations
According to Per Hansen, the strong result is due to the fourth quarter where sales have gone as best.
If you only look at the figures, it's far above expectations. It's outstanding, he says.
The company has had great global success with Ozempic and Wegovy over the past year. The preparations are actually intended to treat type 2 diabetes, but have proven to be very effective in treating obesity.
Tough year on the stock exchange
During the fourth quarter, sales of Wegovy amounted to 19.9 billion Danish kronor. Novo Nordisk simultaneously reports that the number of prescriptions for the preparation on the important American market has increased from 100,000 per week to 200,000.
The sale of Wegovy is important because it's a weight loss preparation that is expected to drive growth. The sale is somewhat below expectations, but we're talking about a few hundred million kronor and I don't think investors will care that much, says Per Hansen.
Novo Nordisk's share has risen sharply on the stock exchange in recent years, but has lost a large part of its value since the peak in the summer.
In December 2024, the stock price collapsed by over 20 percent after a study showed that Novo Nordisk's new weight loss preparation Cagrisema did not meet expectations.
